- Home
- DEI vs RYTM Comparison
DEI vs RYTM Comparison
Compare DEI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEI
- RYTM
- Stock Information
- Founded
- DEI 1971
- RYTM 2008
- Country
- DEI United States
- RYTM United States
- Employees
- DEI N/A
- RYTM N/A
- Industry
- DEI Real Estate Investment Trusts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- DEI Real Estate
- RYTM Health Care
- Exchange
- DEI Nasdaq
- RYTM Nasdaq
- Market Cap
- DEI 2.8B
- RYTM 3.2B
- IPO Year
- DEI 2006
- RYTM 2017
- Fundamental
- Price
- DEI $13.37
- RYTM $59.55
- Analyst Decision
- DEI Buy
- RYTM Strong Buy
- Analyst Count
- DEI 9
- RYTM 12
- Target Price
- DEI $18.50
- RYTM $74.92
- AVG Volume (30 Days)
- DEI 2.7M
- RYTM 901.0K
- Earning Date
- DEI 05-06-2025
- RYTM 05-06-2025
- Dividend Yield
- DEI 5.82%
- RYTM N/A
- EPS Growth
- DEI N/A
- RYTM N/A
- EPS
- DEI 0.13
- RYTM N/A
- Revenue
- DEI $989,071,000.00
- RYTM $130,126,000.00
- Revenue This Year
- DEI $0.22
- RYTM $45.46
- Revenue Next Year
- DEI N/A
- RYTM $63.04
- P/E Ratio
- DEI $100.40
- RYTM N/A
- Revenue Growth
- DEI 0.46
- RYTM 68.06
- 52 Week Low
- DEI $12.39
- RYTM $35.17
- 52 Week High
- DEI $20.50
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- DEI 33.06
- RYTM 59.50
- Support Level
- DEI $12.39
- RYTM $49.86
- Resistance Level
- DEI $14.50
- RYTM $63.11
- Average True Range (ATR)
- DEI 0.86
- RYTM 4.24
- MACD
- DEI -0.25
- RYTM 0.97
- Stochastic Oscillator
- DEI 22.69
- RYTM 79.31
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is a real estate investment trust that acquires, develops, and manages office and multifamily properties in Los Angeles, California and Honolulu, Hawaii in the U.S. The company focuses on owning assets in communities with large supply constraints, such as the affluent neighborhoods of Los Angeles. The vast majority of Douglas Emmett's real estate portfolio is comprised of office buildings in Los Angeles. Most of these assets are located in the areas of Sherman Oaks, Woodland Hills, and Beverly Hills in terms of total square feet. Douglas Emmett derives nearly all of its income in the form of rental revenue from tenants. The vast majority of this also comes from its Los Angeles office buildings. The company's major tenants are legal, financial, and entertainment firms.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.